Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans
William W. Stoops, Justin C. Strickland, Kevin W. Hatton, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 220, pp. 173466-173466
Open Access | Times Cited: 15

Showing 15 citing articles:

Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities
Matteo Carpi, Laura Palagini, Mariana Fernandes, et al.
Neuropharmacology (2023) Vol. 245, pp. 109815-109815
Open Access | Times Cited: 15
A Single-Blind, Randomized, Controlled Contingency Management Trial on Physiological Indices and Biomarkers of Cardiovascular Health in People with Cocaine Use Disorder
William W. Stoops, Thomas Shellenberg, Sean D. Regnier, et al.
Drug and Alcohol Dependence (2025) Vol. 271, pp. 112642-112642
Closed Access
A Preliminary Report on the Effects of Daridorexant in Patients with Comorbid Insomnia and Substance Use Disorders
Marco Di Nicola, Maria Pepe, Lorenzo Bonomo, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 378-378
Open Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Glenn Pascasio, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 7, pp. 647-660
Closed Access | Times Cited: 4
Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Alessandra Matzeu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 9
Orexin-mediated Motivated Arousal and Reward Seeking.
Theresa E. Bjorness, Robert Greene
Peptides (2024) Vol. 180, pp. 171280-171280
Closed Access | Times Cited: 3
Use of drug purchase tasks in medications development research: orexin system regulation of cocaine and drug demand
Justin C. Strickland, Kevin W. Hatton, Lon R. Hays, et al.
Behavioural Pharmacology (2023) Vol. 34, Iss. 5, pp. 275-286
Open Access | Times Cited: 7
Insomnia and the Orexinergic Pathway in the Link with Psychopathology: Effects of DORAs in Insomnia Comorbid with Mental Disturbances
Laura Palagini, Pierre A. Geoffroy, Gaspare Alfì, et al.
Current Sleep Medicine Reports (2024) Vol. 10, Iss. 2, pp. 119-131
Closed Access | Times Cited: 2
Human laboratory models of reward in substance use disorder
Alexandra N. Johansen, Samuel F. Acuff, Justin C. Strickland
Pharmacology Biochemistry and Behavior (2024) Vol. 241, pp. 173803-173803
Closed Access | Times Cited: 2
Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation
Amy C. Beckenstrom, Preciosa Coloma, Gerard R. Dawson, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 147, pp. 105107-105107
Open Access | Times Cited: 5
A dose-ranging study of the physiological and self-reported effects of repeated, rapid infusion of remifentanil in people with opioid use disorder and physical dependence on fentanyl
Joshua A. Lile, Thomas Shellenberg, Shanna Babalonis, et al.
Psychopharmacology (2024) Vol. 241, Iss. 6, pp. 1227-1236
Closed Access | Times Cited: 1
Emerging medications and pharmacological treatment approaches for substance use disorders
Joel S. Raymond, Anastasios Athanasopoulos, Connie J. Badolato, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 248, pp. 173952-173952
Open Access | Times Cited: 1
Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target
Chung Jung Mun, Matthew J. Reid, Sarah Sarandos, et al.
Current Addiction Reports (2024)
Closed Access
Page 1

Scroll to top